Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Positive Efficacy Data Obtained for MDV3100 in PI, PII: Astellas, Medivation
May 3, 2010
- Eisai Licenses Cinitapride from Almirall in China
May 3, 2010
- Lawmakers to Include Lifting of Ban on Online Sales of Drugs in DPJ Manifesto
May 3, 2010
- Sanofi-aventis Licenses New Diabetes Treatment from CureDM Sign
May 3, 2010
- No Call for Lifting of Ban on Kongo Shinryo from DPJ Lawmakers
May 3, 2010
- Kowa, Nitto Denko to Codevelop Transdermal Donepezil Patches
May 3, 2010
- Sato: Patch Test Tape for Allergic Skin Diseases
May 3, 2010
- Nippon Kayaku, Teva-Kowa to Develop G-CSF Biosimilar
May 3, 2010
- Medipolis Completes Cancer Radiotherapy Center in Kagoshima
May 3, 2010
- Biosimilar for EPO Priced at 77% of the Original Drug
May 3, 2010
- Astellas' VESIcare Website Contains “Unsubstantiated Superiority Claims” FDA
May 3, 2010
- Fentos Tape Approved in Japan: Hisamitsu, Kyowa Kirin
May 3, 2010
- Sanofi-aventis Aims at Double-Digit Growth Rate for 4 Years in a Row
May 3, 2010
- Takeda Obtains Approval for 5 Products, Including 1st In-house Product in 11 Years
May 3, 2010
- 6 Drugs, Including Orencia, Recommended for Approval
May 3, 2010
- Approval for Greater Strength Recommended for Pasil/Pazucross
May 3, 2010
- ASKA Aims at Sales of ¥50 Bil. in FY2012
May 3, 2010
- PMDA Must Accelerate Hiring of Reviewers: Mr Osa
May 3, 2010
- MSD to Boost Sales to ¥500 Bil. Within 5 Years
April 26, 2010
- Mr Mitani Proposes Review of PMDA's NDA Review System
April 26, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…